Valuation: Myriad Genetics, Inc.

Capitalization 352M 302M 276M 263M 483M 33.73B 488M 3.29B 1.28B 16B 1.32B 1.29B 55.78B P/E ratio 2026 *
-4.83x
P/E ratio 2027 * -6.62x
Enterprise value 329M 282M 258M 246M 452M 31.54B 456M 3.08B 1.2B 14.96B 1.24B 1.21B 52.15B EV / Sales 2026 *
0.38x
EV / Sales 2027 * 0.35x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-2.95%
1 week-11.92%
Current month-23.79%
1 month-21.13%
3 months-19.38%
6 months-42.99%
Current year-41.14%
1 week 3.62
Extreme 3.62
4.44
1 month 3.62
Extreme 3.62
5.36
Current year 3.62
Extreme 3.62
7.15
1 year 3.62
Extreme 3.62
8.59
3 years 3.62
Extreme 3.62
29.3
5 years 3.62
Extreme 3.62
36.95
10 years 3.62
Extreme 3.62
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer 46 2014-03-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Change 5d. change 1-year change 3-years change Capi.($)
-2.95%-11.92%-11.92%-79.70% 352M
+0.19%+6.95%+138.54%+274.14% 13.06B
-2.95%+1.97%-38.55%-25.40% 10.31B
+0.22%+12.21%+22.44%-2.99% 6.28B
-3.49%+3.02%-13.58%-8.83% 5.81B
+3.81%-20.28% - - 4.15B
+1.16%+8.72%+104.73%+97.54% 4.8B
-1.53%+10.50%-28.11%-34.22% 4.38B
-1.51%+0.92%-13.77%-40.92% 2.9B
+2.14%-5.36%+123.01%-59.12% 2.67B
Average -0.49%+0.12%+31.42%+13.39% 5.47B
Weighted average by Cap. -0.58%+3.24%+42.30%+64.51%

Financials

2026 *2027 *
Net sales 864M 741M 677M 645M 1.19B 82.76B 1.2B 8.08B 3.14B 39.26B 3.24B 3.17B 137B 916M 785M 717M 683M 1.26B 87.71B 1.27B 8.56B 3.33B 41.61B 3.44B 3.36B 145B
Net income -70.45M -60.37M -55.17M -52.56M -96.62M -6.75B -97.57M -659M -256M -3.2B -264M -259M -11.15B -52.68M -45.14M -41.25M -39.3M -72.25M -5.04B -72.96M -492M -191M -2.39B -198M -193M -8.34B
Net Debt -22.91M -19.64M -17.94M -17.1M -31.43M -2.19B -31.74M -214M -83.24M -1.04B -85.99M -84.15M -3.63B -30.17M -25.85M -23.63M -22.51M -41.38M -2.89B -41.79M -282M -110M -1.37B -113M -111M -4.78B
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-05-14 3.620 $ -2.95% 1,673,814
26-05-13 3.730 $ -8.35% 1,989,912
26-05-12 4.070 $ -3.33% 1,175,139
26-05-11 4.210 $ -1.86% 1,158,085
26-05-08 4.290 $ +4.89% 1,983,486
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
3.730USD
Average target price
6.250USD
Spread / Average Target
+67.56%

Quarterly revenue - Rate of surprise